Cargando…
Molecular Characterization of Muellerian Tumors of the Urinary Tract
In the 2016 WHO classification of genitourinary tumors Muellerian tumors of the urinary tract (MTUT) comprise clear cell adenocarcinomas and endometrioid carcinomas. Since these rare tumors remained understudied, we aimed to characterize their molecular background by performing DNA- and RNA-based ta...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8228991/ https://www.ncbi.nlm.nih.gov/pubmed/34200508 http://dx.doi.org/10.3390/genes12060880 |
_version_ | 1783712872037089280 |
---|---|
author | Ortiz-Brüchle, Nadina Wucherpfennig, Sophie Rose, Michael Garczyk, Stefan Bertz, Simone Hartmann, Arndt Reis, Henning Szarvas, Tibor Kiss, András Bremmer, Felix Golz, Reinhard Knüchel, Ruth Gaisa, Nadine T. |
author_facet | Ortiz-Brüchle, Nadina Wucherpfennig, Sophie Rose, Michael Garczyk, Stefan Bertz, Simone Hartmann, Arndt Reis, Henning Szarvas, Tibor Kiss, András Bremmer, Felix Golz, Reinhard Knüchel, Ruth Gaisa, Nadine T. |
author_sort | Ortiz-Brüchle, Nadina |
collection | PubMed |
description | In the 2016 WHO classification of genitourinary tumors Muellerian tumors of the urinary tract (MTUT) comprise clear cell adenocarcinomas and endometrioid carcinomas. Since these rare tumors remained understudied, we aimed to characterize their molecular background by performing DNA- and RNA-based targeted panel sequencing. All tumors (n = 11) presented single nucleotide alterations (SNVs), with ARID1A mutations being the most prevalent (5/11, 45%). Besides frequent ARID1A mutations, loss of ARID1A protein is not a suitable marker since protein expression is (partly) preserved also in mutated cases. Copy number alterations (CNVs) were found in 64% of cases (7/11), exclusively gene amplifications. Interestingly, a functionally relevant RSPO2 gene fusion/microdeletion was discovered in the endometrioid adenocarcinoma case. Comparing our findings with mutational profiles of other tumor entities, absence of TERT promoter mutations argues for a non-urothelial origin. No similarities were also found between MTUT and kidney cancers while parallels were observed for specific SNVs with endometrial carcinomas. In conclusion, immunohistochemical PAX8-positivity and lack of TERT promoter mutations could serve as key diagnostic features in difficult cases. Thus, understanding the molecular background of these tumors helps to refine treatment options and offers the possibility of targeted therapies in cases where needed. |
format | Online Article Text |
id | pubmed-8228991 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-82289912021-06-26 Molecular Characterization of Muellerian Tumors of the Urinary Tract Ortiz-Brüchle, Nadina Wucherpfennig, Sophie Rose, Michael Garczyk, Stefan Bertz, Simone Hartmann, Arndt Reis, Henning Szarvas, Tibor Kiss, András Bremmer, Felix Golz, Reinhard Knüchel, Ruth Gaisa, Nadine T. Genes (Basel) Article In the 2016 WHO classification of genitourinary tumors Muellerian tumors of the urinary tract (MTUT) comprise clear cell adenocarcinomas and endometrioid carcinomas. Since these rare tumors remained understudied, we aimed to characterize their molecular background by performing DNA- and RNA-based targeted panel sequencing. All tumors (n = 11) presented single nucleotide alterations (SNVs), with ARID1A mutations being the most prevalent (5/11, 45%). Besides frequent ARID1A mutations, loss of ARID1A protein is not a suitable marker since protein expression is (partly) preserved also in mutated cases. Copy number alterations (CNVs) were found in 64% of cases (7/11), exclusively gene amplifications. Interestingly, a functionally relevant RSPO2 gene fusion/microdeletion was discovered in the endometrioid adenocarcinoma case. Comparing our findings with mutational profiles of other tumor entities, absence of TERT promoter mutations argues for a non-urothelial origin. No similarities were also found between MTUT and kidney cancers while parallels were observed for specific SNVs with endometrial carcinomas. In conclusion, immunohistochemical PAX8-positivity and lack of TERT promoter mutations could serve as key diagnostic features in difficult cases. Thus, understanding the molecular background of these tumors helps to refine treatment options and offers the possibility of targeted therapies in cases where needed. MDPI 2021-06-07 /pmc/articles/PMC8228991/ /pubmed/34200508 http://dx.doi.org/10.3390/genes12060880 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ortiz-Brüchle, Nadina Wucherpfennig, Sophie Rose, Michael Garczyk, Stefan Bertz, Simone Hartmann, Arndt Reis, Henning Szarvas, Tibor Kiss, András Bremmer, Felix Golz, Reinhard Knüchel, Ruth Gaisa, Nadine T. Molecular Characterization of Muellerian Tumors of the Urinary Tract |
title | Molecular Characterization of Muellerian Tumors of the Urinary Tract |
title_full | Molecular Characterization of Muellerian Tumors of the Urinary Tract |
title_fullStr | Molecular Characterization of Muellerian Tumors of the Urinary Tract |
title_full_unstemmed | Molecular Characterization of Muellerian Tumors of the Urinary Tract |
title_short | Molecular Characterization of Muellerian Tumors of the Urinary Tract |
title_sort | molecular characterization of muellerian tumors of the urinary tract |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8228991/ https://www.ncbi.nlm.nih.gov/pubmed/34200508 http://dx.doi.org/10.3390/genes12060880 |
work_keys_str_mv | AT ortizbruchlenadina molecularcharacterizationofmuelleriantumorsoftheurinarytract AT wucherpfennigsophie molecularcharacterizationofmuelleriantumorsoftheurinarytract AT rosemichael molecularcharacterizationofmuelleriantumorsoftheurinarytract AT garczykstefan molecularcharacterizationofmuelleriantumorsoftheurinarytract AT bertzsimone molecularcharacterizationofmuelleriantumorsoftheurinarytract AT hartmannarndt molecularcharacterizationofmuelleriantumorsoftheurinarytract AT reishenning molecularcharacterizationofmuelleriantumorsoftheurinarytract AT szarvastibor molecularcharacterizationofmuelleriantumorsoftheurinarytract AT kissandras molecularcharacterizationofmuelleriantumorsoftheurinarytract AT bremmerfelix molecularcharacterizationofmuelleriantumorsoftheurinarytract AT golzreinhard molecularcharacterizationofmuelleriantumorsoftheurinarytract AT knuchelruth molecularcharacterizationofmuelleriantumorsoftheurinarytract AT gaisanadinet molecularcharacterizationofmuelleriantumorsoftheurinarytract |